CA3123902A1 - Methods and materials for increasing transcription factor eb polypeptide levels - Google Patents
Methods and materials for increasing transcription factor eb polypeptide levels Download PDFInfo
- Publication number
- CA3123902A1 CA3123902A1 CA3123902A CA3123902A CA3123902A1 CA 3123902 A1 CA3123902 A1 CA 3123902A1 CA 3123902 A CA3123902 A CA 3123902A CA 3123902 A CA3123902 A CA 3123902A CA 3123902 A1 CA3123902 A1 CA 3123902A1
- Authority
- CA
- Canada
- Prior art keywords
- alkyl
- independently selected
- optionally substituted
- substituents independently
- halo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962788049P | 2019-01-03 | 2019-01-03 | |
| US62/788,049 | 2019-01-03 | ||
| US201962879374P | 2019-07-26 | 2019-07-26 | |
| US62/879,374 | 2019-07-26 | ||
| PCT/US2020/012268 WO2020142748A1 (en) | 2019-01-03 | 2020-01-03 | Methods and materials for increasing transcription factor eb polypeptide levels |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3123902A1 true CA3123902A1 (en) | 2020-07-09 |
Family
ID=71406977
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3123902A Pending CA3123902A1 (en) | 2019-01-03 | 2020-01-03 | Methods and materials for increasing transcription factor eb polypeptide levels |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US12286442B2 (enExample) |
| EP (1) | EP3906033A4 (enExample) |
| JP (1) | JP7566753B2 (enExample) |
| KR (1) | KR102904932B1 (enExample) |
| CN (1) | CN113316453B (enExample) |
| AU (1) | AU2020204717B2 (enExample) |
| BR (1) | BR112021012950A2 (enExample) |
| CA (1) | CA3123902A1 (enExample) |
| IL (1) | IL284403A (enExample) |
| MX (1) | MX2021008152A (enExample) |
| SG (1) | SG11202105685TA (enExample) |
| WO (1) | WO2020142748A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022013684A1 (en) | 2020-07-11 | 2022-01-20 | Pfizer Inc. | Antiviral heteroaryl ketone derivatives |
| US11351149B2 (en) | 2020-09-03 | 2022-06-07 | Pfizer Inc. | Nitrile-containing antiviral compounds |
| CZ309449B6 (cs) * | 2020-12-24 | 2023-01-25 | Ústav experimentální botaniky AV ČR, v. v. i. | Chinazolinové deriváty jako selektivní inhibitory cyklooxygenázy-1 |
| CN113248518B (zh) * | 2021-06-21 | 2022-03-25 | 山东大学 | 嘧啶哌嗪类衍生物及其制备方法与应用 |
| WO2025026988A1 (en) * | 2023-07-28 | 2025-02-06 | Theranexus | Mutated tfeb for treating lysosomal disorders |
| CN119818678A (zh) * | 2024-12-24 | 2025-04-15 | 广州医科大学附属妇女儿童医疗中心 | Tfeb在制备变应性鼻炎的药物中的应用 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
| US5716981A (en) | 1993-07-19 | 1998-02-10 | Angiogenesis Technologies, Inc. | Anti-angiogenic compositions and methods of use |
| US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
| ES2266258T3 (es) | 2000-09-15 | 2007-03-01 | Vertex Pharmaceuticals Incorporated | Compuestos de pirazol utiles como inhibidores de proteina cinasas. |
| JP2005503425A (ja) | 2001-05-24 | 2005-02-03 | アレックザ モレキュラー デリヴァリー コーポレイション | 所定の吸入ルートによる薬剤エステルの送出 |
| US20030158195A1 (en) * | 2001-12-21 | 2003-08-21 | Cywin Charles L. | 1,6 naphthyridines useful as inhibitors of SYK kinase |
| WO2004037814A1 (en) * | 2002-10-25 | 2004-05-06 | Vertex Pharmaceuticals Incorporated | Indazolinone compositions useful as kinase inhibitors |
| CL2004000409A1 (es) | 2003-03-03 | 2005-01-07 | Vertex Pharma | Compuestos derivados de 2-(cilo sustituido)-1-(amino u oxi sustituido)-quinazolina, inhibidores de canales ionicos de sodio y calcio dependientes de voltaje; composicion farmaceutica; y uso del compuesto en el tratamiento de dolor agudo, cronico, neu |
| US7198926B2 (en) | 2003-05-08 | 2007-04-03 | E. I. Du Pont De Nemours And Company | Preparation of (E)- and (Z)-2-methyl-2-butenoic acids |
| WO2004101512A2 (en) * | 2003-05-13 | 2004-11-25 | Smithkline Beecham Corporation | Naphthyridine integrase inhibitors |
| US20090209536A1 (en) * | 2007-06-17 | 2009-08-20 | Kalypsys, Inc. | Aminoquinazoline cannabinoid receptor modulators for treatment of disease |
| CN101917999A (zh) * | 2007-11-07 | 2010-12-15 | 弗尔德里克斯制药股份有限公司 | 蛋白质运输的调节 |
| WO2010015520A1 (de) | 2008-08-05 | 2010-02-11 | Boehringer Ingelheim International Gmbh | Substituierte naphthyridine und ihre verwendung als arzneimittel |
| EP2313406B1 (de) * | 2008-08-05 | 2015-02-25 | Boehringer Ingelheim International GmbH | 4-dimethylaminophenyl-substituierte napththyridine und ihre verwendung als arzneimittel |
| GB201007203D0 (en) * | 2010-04-29 | 2010-06-16 | Glaxo Group Ltd | Novel compounds |
| GB201007347D0 (en) * | 2010-04-30 | 2010-06-16 | Karus Therapeutics Ltd | Compounds |
| EP2922540A1 (en) | 2012-11-20 | 2015-09-30 | F. Hoffmann-La Roche AG | Substituted 1,6-naphthyridines |
| US20170354666A1 (en) * | 2014-11-19 | 2017-12-14 | Rush University Medical Center | Compositions and methods for treating lysosomal disorders |
| WO2018089499A1 (en) | 2016-11-08 | 2018-05-17 | Navitor Pharmaceuticals, Inc. | PHENYL AMINO PIPERIDINE mTORC INHIBITORS AND USES THEREOF |
| WO2018089493A1 (en) | 2016-11-08 | 2018-05-17 | Navitor Pharmaceuticals, Inc. | PYRROLE mTORC INHIBITORS AND USES THEREOF |
| WO2018089433A1 (en) * | 2016-11-08 | 2018-05-17 | Navitor Pharmaceuticals, Inc. | PHENYL mTORC INHIBITORS AND USES THEREOF |
| WO2018191146A1 (en) | 2017-04-10 | 2018-10-18 | Navitor Pharmaceuticals, Inc. | Heteroaryl rheb inhibitors and uses thereof |
-
2020
- 2020-01-03 JP JP2021538743A patent/JP7566753B2/ja active Active
- 2020-01-03 SG SG11202105685TA patent/SG11202105685TA/en unknown
- 2020-01-03 MX MX2021008152A patent/MX2021008152A/es unknown
- 2020-01-03 BR BR112021012950-2A patent/BR112021012950A2/pt unknown
- 2020-01-03 KR KR1020217022772A patent/KR102904932B1/ko active Active
- 2020-01-03 US US17/420,597 patent/US12286442B2/en active Active
- 2020-01-03 AU AU2020204717A patent/AU2020204717B2/en active Active
- 2020-01-03 WO PCT/US2020/012268 patent/WO2020142748A1/en not_active Ceased
- 2020-01-03 CN CN202080007921.4A patent/CN113316453B/zh active Active
- 2020-01-03 CA CA3123902A patent/CA3123902A1/en active Pending
- 2020-01-03 EP EP20736104.9A patent/EP3906033A4/en active Pending
-
2021
- 2021-06-27 IL IL284403A patent/IL284403A/en unknown
-
2025
- 2025-01-23 US US19/035,805 patent/US20250382309A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP7566753B2 (ja) | 2024-10-15 |
| JP2022516631A (ja) | 2022-03-01 |
| US12286442B2 (en) | 2025-04-29 |
| IL284403A (en) | 2021-08-31 |
| BR112021012950A2 (pt) | 2021-09-14 |
| US20220112218A1 (en) | 2022-04-14 |
| EP3906033A4 (en) | 2022-11-09 |
| SG11202105685TA (en) | 2021-06-29 |
| KR102904932B1 (ko) | 2025-12-26 |
| AU2020204717B2 (en) | 2025-01-16 |
| CN113316453A (zh) | 2021-08-27 |
| WO2020142748A1 (en) | 2020-07-09 |
| US20250382309A1 (en) | 2025-12-18 |
| EP3906033A1 (en) | 2021-11-10 |
| CN113316453B (zh) | 2025-12-23 |
| MX2021008152A (es) | 2021-10-13 |
| AU2020204717A1 (en) | 2021-06-10 |
| KR20210111787A (ko) | 2021-09-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7675777B2 (ja) | 免疫調節剤としての複素環式化合物 | |
| AU2020204717B2 (en) | Methods and materials for increasing transcription factor EB polypeptide levels | |
| US10138249B2 (en) | Triazolopyridines and triazolopyrazines as LSD1 inhibitors | |
| EP3105226B1 (en) | Cyclopropylamines as lsd1 inhibitors | |
| MX2014014658A (es) | Heterociclos capaces de modular las respuestas de los linfocitos t, y métodos de uso de los mismos. | |
| AU2015210833A1 (en) | Dihydropyrrolopyridine inhibitors of ROR-gamma | |
| JP2017036317A (ja) | インダゾール−３−カルボキサミドおよびＷＮＴ／β−カテニンシグナル伝達経路阻害剤としてのそれらの使用 | |
| JP6851825B2 (ja) | 非アポトーシス性の制御された細胞死の阻害剤としてのスピロキノキサリン誘導体 | |
| BRPI0908417A2 (pt) | composto, pró-droga, agente farmacêutico, método para inibir smo e para a profilacia ou tratamento de câncer em um mamídero, e, uso do composto | |
| BRPI0808746B1 (pt) | Derivado de purinila como modulador do canal de potássio, composição farmacêutica, e, uso de um derivado de purinila. | |
| EP3217982B1 (en) | Spiropyrazine derivatives as inhibitors of non-apoptotic regulated cell-death | |
| CA3150492A1 (en) | Usp30 inhibitors and uses thereof | |
| WO2020172565A1 (en) | Methods and materials for increasing or maintaining nicotinamide mononucleotide adenylyl transferase-2 (nmnat2) polypeptide levels | |
| JPWO2016136928A1 (ja) | イミダゾオキサジンの結晶、当該結晶を含む医薬組成物、及び当該結晶の製造方法 | |
| AU2006271518A1 (en) | N(arylalkyl)-1h-pyrrolopyridine-2-carboxamide derivatives, preparation and therapeutic use thereof | |
| KR20060135035A (ko) | 유사분열 키네신 억제제 | |
| CN103204816B (zh) | 哌嗪基嘧啶类衍生物及其制备方法和用途 | |
| CA3090439A1 (en) | Compound having bet inhibitory activity and preparation method and use therefor | |
| RU2838857C2 (ru) | Способы и материалы для повышения уровней полипептида фактора транскрипции eb | |
| WO2015090224A1 (zh) | 新型哌啶氨甲酰类化合物、制备方法及其用途 | |
| WO2022109292A1 (en) | Methods and materials for inhibiting cb1 activity | |
| EP4027987A1 (en) | Methods and materials for increasing level of phosphorylated ampk protein | |
| JP2010534231A (ja) | デュシェンヌ型筋ジストロフィーを治療するための化合物 | |
| HK1229788B (en) | Dihydropyrrolopyridine inhibitors of ror-gamma | |
| HK1229788A1 (en) | Dihydropyrrolopyridine inhibitors of ror-gamma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220824 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D120 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: VOLUNTARY SUBMISSION OF PRIOR ART RECEIVED Effective date: 20241024 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250102 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250102 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250102 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250212 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D123 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIOR ART DISCLOSURE DETERMINED COMPLIANT Effective date: 20250327 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250327 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250422 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20250822 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250915 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20251104 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20251104 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251223 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251223 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D120 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: VOLUNTARY SUBMISSION OF PRIOR ART RECEIVED Effective date: 20260308 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D120 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: VOLUNTARY SUBMISSION OF PRIOR ART RECEIVED Effective date: 20260309 Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D123 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIOR ART DISCLOSURE DETERMINED COMPLIANT Effective date: 20260309 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260309 Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260309 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D123 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIOR ART DISCLOSURE DETERMINED COMPLIANT Effective date: 20260318 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260318 |